New RSV Vaccine Significantly Reduces Hospital Admissions in Babies: A Breakthrough for Infant Health

A new UK study is bringing optimism to parents and healthcare professionals alike: a vaccine administered during pregnancy has been found to greatly lower the risk of babies being hospitalized with a severe lung infection called RSV. The findings are encouraging and suggest that a single jab during pregnancy could prevent thousands of babies from requiring hospitalization each winter.

The RSV Threat: A Leading Cause of Infant Hospitalisation

RSV, or respiratory syncytial virus, is extremely prevalent in our society nowadays among young children. Although it’s mild and cold-like, RSV will lead to more severe complications. Sometimes, it can result in bronchiolitis or pneumonia, especially in infants under six years. 

These youngest babies are one of the top reasons for hospitalisation, not only in the UK but at a worldwide level. Due to this chronic issue, a particular RSV vaccine was introduced for pregnant women across the UK in summer 2024. Now, scientists are quantifying its effect in real-world environments and coming up with dramatic findings. 

A New Strategy: Vaccination During Pregnancy

The research, which was led by the Universities of Edinburgh and Leicester, monitored 537 babies who were hospitalized in England and Scotland during winter 2024–2025. Of these, 391 had tested positive for RSV. What researchers discovered was that those babies whose mothers had been vaccinated while pregnant were much less likely to be among those hospitalized.

Mothers whose babies didn’t catch RSV were two times as likely to have been vaccinated as mothers of RSV-infected babies—41% to 19%. And timing was also crucial. Women who got the vaccine more than two weeks before they gave birth experienced a 72% decrease in RSV-related hospitalizations for their babies. Those who were vaccinated at any time before birth still enjoyed protection, albeit a slightly diminished one, of about 58%.

Why This Matters?

The vaccine pushes the immune system of the mother to create antibodies containing proteins that defend against infection. Those antibodies are transferred to the infant via the placenta, providing the child with an early advantage in combating RSV in their most susceptible months.

Dr Thomas Williams, the lead author and pediatric consultant from the University of Edinburgh, described the findings as a “breakthrough” in preventing illness in early infants. “Now that we have the option of an effective RSV vaccine proven to greatly lower the risk of hospitalization in young babies, we now have a genuine chance to protect mothers and their infants better this winter,” he said.

Room for Improvement in Vaccine Uptake

Despite all the positive findings, the uptake of the vaccine hasn’t been anticipated at the expected level. Roughly half of pregnant women in England and Scotland are getting this. This is troubling data, knowing how effective it appears. 

Experts attribute this gap, in part, to unawareness. Most pregnant women just haven’t heard about the vaccine or aren’t aware of just how bad RSV can be. Some are also afraid of introducing new drugs during pregnancy, although clinical trials have proven the vaccine is safe for both mother and child.

The Science Behind It

Professor Damian Roland from Leicester University, also a participant in the study, highlighted the wider benefit of prevention in public health. “This is exactly in line with the NHS plan to move more towards prevention and away from treatment,” he told us. “It’s time to think about how to deliver RSV vaccines so more women—and their babies—can gain from it.

The research findings are particularly relevant as we move forward to the winter months, when RSV infection usually peaks. Hospitals receive a crush of ill infants with respiratory difficulties brought about by RSV infection. In very bad years, this can be a tremendous burden on pediatric intensive care units.

The scientists conducting the study emphasize that the ideal time to receive the vaccination is after 28 weeks of pregnancy. This allows enough time for the mother’s body to be able to produce antibodies and transfer them to the baby during birth. Nonetheless, vaccination can still be administered safely up until the time of delivery.

Funding for this research came as a result of collaboration among some of the biggest institutions, such as the Universities of Bristol, Oxford, Queen’s University Belfast, UCL, and Imperial College London. 

Looking Ahead: Protecting the Next Generation

Ultimately, this research provides something genuinely remarkable: an easy, evidence-based means of protecting serious illness in the youngest and most susceptible among us. It is evident, and the potential value is immense. Greater awareness, enhanced access, and a concerted public health campaign could equal fewer babies in hospital beds this winter—and greater reassurance for new parents everywhere.

It is rare that we witness such a sudden decline in hospitalization rates with one intervention. But this vaccine, administered at the correct time, is capable of altering the trajectory of a baby’s first few months of life. If you are pregnant or soon to become pregnant, discuss the RSV vaccine with your doctor. It is one small step that can make a big difference—for both you and your baby. Feel free to share your views on this in the comments.

Reference:

Williams, Thomas C. Middleton, Catriona M et al. Bivalent prefusion F vaccination in pregnancy and respiratory syncytial virus hospitalisation in infants in the UK: results of a multicentre, test-negative, case-control study. The Lancet Child & Adolescent Health. DOI:10.1016/S2352-4642(25)00155-5

Medical Dialogues

Frequently Asked Questions